Professional Reference articles are designed for health professionals to use. They are written by UK doctors and based on research evidence, UK and European Guidelines. You may find the Measles article more useful, or one of our other health articles.
Treatment of almost all medical conditions has been affected by the COVID-19 pandemic. NICE has issued rapid update guidelines in relation to many of these. This guidance is changing frequently. Please visit https://www.nice.org.uk/covid-19 to see if there is temporary guidance issued by NICE in relation to the management of this condition, which may vary from the information given below.
Measles is the archetypal childhood infection - whilst self-limiting in most, it is not a trivial disease.
Immunisation programmes in the UK and elsewhere had limited many modern clinicians' exposure to the disease. Falls in the uptake of immunisation following inappropriate concerns about the measles, mumps and rubella (MMR) vaccine safety have increased the susceptible population; however, it is hoped this was addressed by a vaccine catch-up programme and patient education about the vaccination.
Measles has been on the rise in several regions including Europe, North America and Southeast Asia since 2008. The World Health Organization (WHO) attributes much of this reversal of progress to the global economic situation.
- Measles is an acute infection caused by a single-stranded RNA Morbillivirus from the paramyxovirus family.
- It is one of the most contagious infectious diseases.
- Transmission is airborne via respiratory droplets. These spread to surfaces and the virus can remain transmissible for up to two hours, removing the need for direct person-to-person contact.
- Measles has an incubation period of about 10 days, with a further 2-4 days of prodromal symptoms (including malaise, fever, and cough) before the characteristic skin rash develops.
- The person is infectious from when symptoms first appear (around four days before the rash appears) to four days after the onset of the rash.
- Measles infects, via the respiratory tract, nearly all susceptible people who come into contact with it (on average, within a susceptible population, 15-20 people will be infected from a single case). Once infected, the person develops lifelong immunity.
- The epidemiology of measles is affected by uptake of vaccination. With extra efforts being made to improve the efficacy of vaccination programmes and a recovery of uptake after vaccine scares, the rates of confirmed measles are reducing in the UK.
- The number of people with confirmed measles in England and Wales in 2019 was 810 which is significantly lower than 2032 in 2012.
In 2018-2019 MMR (1) coverage at 5 years was 94.5%, down from 94.9% in 2017-18 and below the 95% target. MMR (2) coverage at 5 years was 86.4% (down from 87.2% in 2017-18).
- In the USA, endemic measles has been virtually eradicated although imported measles still occasionally occurs due to international travel and visitors from abroad.
The following features are strongly suggestive of measles:
- Rash for at least three days.
- Fever for at least one day and at least one of the following:
- This lasts 2-4 days with fever, cough, runny nose, mild conjunctivitis and diarrhoea.
- Koplik's spots are pathognomonic and appear on the buccal mucosa - opposite the second molar teeth - as small, red spots, each with a bluish-white speck (sometimes compared with a grain of rice) in the centre. They occur in 60-70% of patients during the prodrome and for up to 2-3 days after the rash disappears.
- Rash (morbilliform = measles-like):
- This is first seen on the forehead and neck and spreads, involving the trunk and finally the limbs, over 3-4 days. It may become confluent in some areas.
- The rash then fades after 3-4 days in the order of its appearance.
- It leaves behind a brownish discolouration, sometimes accompanied by fine desquamation.
- Often, there is high fever (may be >40°C) and a non-productive cough, with the patient being clearly ill.
- Also, swelling around the eyes and photophobia may be present.
Clinical recovery in uncomplicated measles tends to occur soon after the appearance of the rash.
Case definition of measles helps to identify cases for notification but clinical diagnosis is unreliable, particularly in countries with low incidence of the disease, so laboratory confirmation is required .
Options available for the laboratory diagnosis of measles:
- Salivary swab or serum sample for measles-specific immunoglobulin M (IgM) taken within six weeks of onset.
- RNA detection in salivary swabs or other samples.
The latest guidelines from Public Health England (PHE) state that oral fluid (OF) is the optimal sample for measles surveillance. Kits can be requested from PHE. These samples are minimally invasive and are more acceptable than serum for confirming cases in infants and children. Importantly, OF can be tested for IgM, IgG and measles RNA. In the absence of OF, serum AND a mouth swab should be sent instead. It also deals with secondary transmission identification and risk assessment, in order for timely post-exposure prophylaxis.
- Parvovirus B19.
- Scarlet fever.
- Human herpesvirus type 7.
- Kawasaki disease.
- Toxic shock syndrome.
- Human immunodeficiency virus (HIV).
- Secondary syphilis.
- Drug allergy.
There can be significant public health implications and these need careful consideration as a matter of urgency alongside management of the affected individual.
- Uncomplicated measles is usually self-limiting and treatment is mainly symptomatic, with paracetamol or ibuprofen and with plenty of fluids. Patients should remain at home to limit disease spread.
- Monitor patients carefully for signs of complications and consider hospitalisation if these appear.
Public health management
Even in countries with a low incidence, suspected cases of measles require urgent public health action. Appropriate public health measures are detailed in PHE guidance. The rationale for this is clear and worthy of defining:
- Early detection of outbreaks can prompt vaccination campaigns to limit spread where appropriate.
- Vulnerable contacts (infants, pregnant women and immunocompromised individuals) should be identified for post-exposure prophylaxis where appropriate.
- Any susceptible healthcare workers need urgent assessment because they can be a source of transmission.
- Even healthy contacts (including unimmunised children and adults) may benefit from post-exposure vaccination.
Rates of complications vary by age, geographical region and outbreak but are estimated to be in the order of 10-20% in developed countries. They increase where factors such as co-existent immunodeficiency, malnutrition, vitamin A deficiency, pregnancy and high exposure levels due to overcrowding exist.
- Otitis media occurs in 7-9% of cases.
- Bronchopneumonia occurs in up to 1-6% of cases, producing serious respiratory difficulties and it accounts for 56-86% of deaths.The infecting organism is usually Staphylococcus aureus or secondary viral infection with herpes simplex or adenovirus. Lobar pneumonia can occur and is caused by Streptococcus pneumoniae. Other secondary bacterial infections include cervical adenitis and otitis media.
- Giant cell pneumonitis in immunocompromised patients presents 2-3 weeks following infection with measles, with worsening breathing.
Measles is associated with three different encephalitic diseases:
- Acute demyelinating encephalitis - this occurs in 1/1,000 cases of infection. It occurs within two weeks of the rash appearing, usually with seizures often accompanied by fever, irritability, headache and changing consciousness that may progress to coma. It is believed to be a neuro-allergic process. It carries a 10-15% mortality rate and 25% of children have permanent brain damage.
- Subacute sclerosing panencephalitis - this is a rare complication occurring in 1 in 10,000 infected children in developed countries. It is more common in boys and, where the initial infection occurs before the age of 2 years, onset is usually 5-10 years after apparently normal measles, with disturbance in intellect and personality, behavioural disorders and worsening school work. This is followed by seizures, signs of extrapyramidal and pyramidal disease and, finally, decerebrate rigidity and death.
- Measles inclusion body encephalitis - this occurs in the immunocompromised 1-7 months following exposure and is progressive over months. It is largely fatal and, of the approximate 15% of survivors, all will have neurological sequelae.
The reduced incidence of measles (brought about by vaccination) has caused the almost total disappearance of subacute sclerosing panencephalitis in England and Wales.
Measles is commonly accompanied by diarrhoea due to secondary bacterial or protozoal infections. This is particularly significant in malnourished individuals. Clinical hepatitis and hypocalcaemia may also occur, more usually in adults.
Vitamin A deficiency and visual impairment
Those with borderline vitamin A deficiency are at greater risk of death and severe sight impairment from measles. Vitamin A deficiency manifests itself as xerophthalmia and is an important cause of sight impairment worldwide. The WHO recommends high-dose vitamin A for all children with measles in countries where the case fatality rate is greater than 1%.
Vitamin A is sometimes used to reduce the risk of complications in people with confirmed measles.
Infants and adults show delayed recovery from the lymphopenia that infection with measles causes. Even after lymphocyte counts have normalised, immunodeficiency persists for many weeks and this is thought to be a major contributor to the high all-cause mortality following acute measles worldwide.
Like many infections, measles can be more severe in pregnancy, as a potentially fatal pneumonitis may follow. Measles is also associated with increased risk of miscarriage, prematurity, and low birth weight, but not with congenital malformation.
Disease severity varies from mild (usually in the well-fed child) to severe (usually in the malnourished or immunosuppressed patient). However, severe measles can occasionally present in a previously healthy child and particularly in young adults who have not been vaccinated or exposed to the virus naturally.
- Case fatality ratio estimates vary from <0.01% in industrialised countries to >5% in developing countries.
- Measles remains a considerable cause of childhood mortality worldwide, with estimates that >100,000 fatal cases occur each year.
- Worldwide, measles is the leading cause of vaccine-preventable death.
- Complication and mortality rates are highest in infancy and lowest in those aged 1-9 years, before rising again into adulthood.
- The measles vaccine and vitamin A are proven effective interventions to prevent measles mortality in children.
- See the separate Measles, Mumps and Rubella (MMR) Vaccination article.
- MMR vaccination may be effective if given to those who are susceptible (over 6 months old), ideally within 72 hours of exposure.
- If the individual is already incubating measles, mumps or rubella, the MMR vaccination will not exacerbate the symptoms.
- As response to MMR in infants is sub-optimal, where the vaccine has been given before 12 months of age, immunisation with two further doses of MMR should be given at the normal ages.
- Human normal immunoglobulin should be considered within five days of exposure for children and adults with compromised immune systems.
- Pregnant women who are exposed to measles may also be considered for intramuscular normal immunoglobulin.
- A very high proportion of pregnant women will be immune and therefore normal immunoglobulin is only offered to women who are likely to be susceptible.
- Recommendations for post-exposure prophylaxis for infants, immunosuppressed and pregnant contacts have recently been changed.
Further reading and references
Barbosa JR, Martins AS, Ruivo J, et al; Fever and Rash: Revisiting Measles. Acta Med Port. 2018 Jun 2931(6):341-345. doi: 10.20344/amp.9776. Epub 2018 Jun 29.
Brix T, Guo C, Magnenat E, et al; Measles: from a simple rash - to a fatal outcome? Rev Med Suisse. 2019 Oct 915(666):1807-1811.
Caudron Q, Mahmud AS, Metcalf CJ, et al; Predictability in a highly stochastic system: final size of measles epidemics in small populations. J R Soc Interface. 2015 Jan 612(102):20141125. doi: 10.1098/rsif.2014.1125.
Global Measles and Rubella Strategic Plan 2012-2020; World Health Organization
Measles; NICE CKS, March 2018 (UK access only)
Confirmed cases of measles, mumps and rubella in England and Wales: 1996 to 2019; Public Health England, April 2020
Childhood Vaccination Coverage Statistics - England 2018-19; NHS Digital, Sept 2019
Papania MJ, Wallace GS, Rota PA, et al; Elimination of endemic measles, rubella, and congenital rubella syndrome from the Western hemisphere: the US experience. JAMA Pediatr. 2014 Feb168(2):148-55. doi: 10.1001/jamapediatrics.2013.4342.
PHE National Measles Guidelines; Public Health England (Aug 2017, updated 2019)
Kondamudi NP, Waymack JR; Measles. StatPearls Publishing 2020 Jan. 2020 Aug 10.
Madhi SA, Levine OS, Hajjeh R, et al; Vaccines to prevent pneumonia and improve child survival. Bull World Health Organ. 2008 May86(5):365-72.
Paules CI, Marston HD, Fauci AS; Measles in 2019 - Going Backward. N Engl J Med. 2019 Jun 6380(23):2185-2187. doi: 10.1056/NEJMp1905099. Epub 2019 Apr 17.
Rota PA, Moss WJ, Takeda M, et al; Measles. Nat Rev Dis Primers. 2016 Jul 142:16049. doi: 10.1038/nrdp.2016.49.
Measles; World Health Organization
Measles: post-exposure prophylaxis; Public Health England (May 2009 - last updated July 2019)